Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, C4 Therapeutics Inc’s stock clocked out at $3.66, down -4.56% from its previous closing price of $3.84. In other words, the price has decreased by -$4.56 from its previous closing price. On the day, 0.98 million shares were traded. CCCC stock price reached its highest trading level at $3.795 during the session, while it also had its lowest trading level at $3.47.
Ratios:
To gain a deeper understanding of CCCC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.31 and its Current Ratio is at 6.31. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Upgraded its rating to Overweight and sets its target price to $12 from $8 previously.
On November 18, 2024, Stephens started tracking the stock assigning a Equal-Weight rating and target price of $4.
JP Morgan Upgraded its Underweight to Neutral on January 29, 2024, while the target price for the stock was maintained at $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 18 ’24 when Salter Malcolm bought 13,000 shares for $4.19 per share.
Salter Malcolm bought 13,000 shares of CCCC for $83,321 on Oct 18 ’24. On Oct 11 ’24, another insider, Salter Malcolm, who serves as the Director of the company, bought 8,561 shares for $5.38 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 258708688 and an Enterprise Value of 70162536. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.68 while its Price-to-Book (P/B) ratio in mrq is 1.07. Its current Enterprise Value per Revenue stands at 2.084 whereas that against EBITDA is -0.609.
Stock Price History:
The Beta on a monthly basis for CCCC is 2.97, which has changed by -0.4649635 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $11.88, while it has fallen to a 52-week low of $3.43. The 50-Day Moving Average of the stock is -18.62%, while the 200-Day Moving Average is calculated to be -34.92%.
Shares Statistics:
It appears that CCCC traded 1.37M shares on average per day over the past three months and 1742710 shares per day over the past ten days. A total of 70.56M shares are outstanding, with a floating share count of 56.91M. Insiders hold about 19.38% of the company’s shares, while institutions hold 83.30% stake in the company. Shares short for CCCC as of 1734048000 were 8869471 with a Short Ratio of 6.29, compared to 1731628800 on 7401252. Therefore, it implies a Short% of Shares Outstanding of 8869471 and a Short% of Float of 15.22.
